famotidine has been researched along with Hepatocellular Carcinoma in 2 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Unresectable hepatocellular carcinoma (HCC) has a poor prognosis and little sensitivity to anticancer agents." | 1.28 | [Intraarterial combination immunotherapy in hepatocellular carcinoma]. ( Hazama, S; Iizuka, N; Murakami, T; Oka, M; Shimizu, R; Suzuki, T; Yano, K; Yoshino, S, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Oka, M | 2 |
| Hazama, S | 2 |
| Yoshino, S | 2 |
| Shimoda, K | 1 |
| Suzuki, M | 1 |
| Shimizu, R | 2 |
| Yano, K | 2 |
| Nishida, M | 1 |
| Suzuki, T | 2 |
| Iizuka, N | 1 |
| Murakami, T | 1 |
1 trial available for famotidine and Hepatocellular Carcinoma
| Article | Year |
|---|---|
Intraarterial combined immunochemotherapy for unresectable hepatocellular carcinoma: preliminary results.
Topics: Aged; Carcinoma, Hepatocellular; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Famotidin | 1994 |
1 other study available for famotidine and Hepatocellular Carcinoma
| Article | Year |
|---|---|
[Intraarterial combination immunotherapy in hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Products; Carcinoma, Hepatocellular; Cycl | 1990 |